[go: up one dir, main page]

AR057990A1 - Imidazolinas 4,4,5,5 tetrasustituidas y un proceso para su sintesis - Google Patents

Imidazolinas 4,4,5,5 tetrasustituidas y un proceso para su sintesis

Info

Publication number
AR057990A1
AR057990A1 ARP060105272A ARP060105272A AR057990A1 AR 057990 A1 AR057990 A1 AR 057990A1 AR P060105272 A ARP060105272 A AR P060105272A AR P060105272 A ARP060105272 A AR P060105272A AR 057990 A1 AR057990 A1 AR 057990A1
Authority
AR
Argentina
Prior art keywords
ch2ch3
piperidinyl
och3
morpholinyl
ch2ch2oh
Prior art date
Application number
ARP060105272A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057990A1 publication Critical patent/AR057990A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos descriptos muestran actividad como agentes antitumorales. Estas imidazolinas son inhibidores de la interaccion entre P53 y MDM2 (proteínas). Reivindicacion 1: Un compuesto de formula (1), en la que X1 y X2 son halogeno, acetileno, ciano, trifluorometilo o nitro; R1 y R2 se seleccionan de entre el grupo que consiste en -H, -CH3, - CH2CH3, -CH2OH y -CH2OCH3 con la condicion de que y no sean ambos hidrogeno; R3 es -H o -C(=O)-R7; y cuando R6 es hidrogeno entonces, R4 es -OCH3, - OCH2CH3, -OCH2CH2F, -OCH2CH2OCH3, u -OCH(CH3)2; R5 es -H, -halogeno, -CH3, -CF3, -OCH3, -C(CH3)2, -ciclopropilo, ciano, -C(CH3)3, -C(CH3)2OR (en la que R es -H, -CH3, -CH2-CH3, -C(CH3)2CH-OR (en la que R es -H, -CH3, -CH(CH3)2, -CH2CH2OH o - CH2CH2OCH3), -C(CH3)2CN, -C(CH3)2COR (en la que R es -CH3), -C(CH3)2COOR (en la que R es -H, -CH3, -CH2CH3 o -CH-(CH3)2), -C(CH3)2CONRaRb (en la que Ra es -H, -CH3, y Rb es -H o -CH3), -SR (en la que R es -CH3 o -CH2CH3),o -SO2R (en la que R es - CH3, -CH2CH3, 1-pirrolidina, -NH-terc-butilo o -N(CH3)2); y cuando R6 no es hidrogeno entonces R4 es -OCH3, -OCH2CH3, -OCH2CH2F, -OCH2CH2OCH3, o -OCH(CH3)2; R5 es hidrogeno, -CI, -OCH3, terc-butiIo o -N(CH3)2; R6 es -CI, ciclopropilo, -SO2R (en la que R es -CH3, -CH2CH3, 1-pirrolidina, -NH-terc-butilo, -NH2, o -N(CH3)2); y R7 se selecciona del grupo que consiste en i) -CH3, -CH(CH3)2, -CH2CH(CH3)2, ciclopropilo, ciclobutilo, -CH2CH2Ph, 2-furanilo, fenilo o fenilo sustituido por cloro, -OCH3 o ciano, ii) 4-morfolinilo, 1-piperidinilo, 4-tiomorfolinilo o 4-tiomorfolinil-1,1-dioxido, iii) -NRc2 (en la que Rc es hidrogeno, -CH3, -CH2CH3. -CH2CH2OH, -CH2CH2OCH3 o -CH2CH(OH)CH2OH), iv) una piperazina sustituida de la formula (2), en la que R se selecciona del grupo que consiste en a) hidrogeno, b) alquilo inferior, c) -CH(CH3)2, d) -CH(CH2CH3)2, e) ciclopentilo, f) -CH2CH(OH)CH3, g) -CH2CF3, h) -CH2CH(OH)CF3, i) -CH2C(CH3)2OH, j) -CH2-[4-N-metilpiperidinilo], k) -CH2CH2Rd (en la que Rd es -OH, -OCH3, -OCH2CH2OH, -OCH2CH2OCH3, -CN, -CF3, -SO2CH3, -SO2NH2, -SO2N(CH3)2, -CONH2, -CON(CH3)2, -NH2, -NHCOCH3, -NHSO2CH3, -N(CH3)2, -N(CH2CH3)2, -N(CH2CH2CH3)2, 1-pirrolidinilo, 1-piperidinilo, 4-morfolinilo, 2-isotiazolidinil-1 1-dioxido, o 2-tetrahidrofuranilo), l) -CH2CH2CH2Re (en la que Re es -OH, -OCH3, -SO2CH3, -SO2CH2CH3, -SO2N(CH3)2, -CN, -N(CH3)2, -N(CH2CH2CH3)2, 1-imidazolilo, 1-pirrolidinilo, 1-piperidinilo, 4-morfolinilo, -COOCH3, -COOCH2CH3, -COOC(CH3)3, -CON(CH3)2, -CO-Rf (en la que Rf es -CH3, -CH2CH3, ciclopropilo, fenilo, 2-tienilo, 3-tienilo, 2-furanilo, 3-furanilo), -COCH2-Rg (en la que Rg es 1-1, -NHCH2CH2OH, -NHCH2CH2OCH3, -NHCH2CH2N(CH3)2, 1-piperidinilo, 1-(piperidinil-4-metanol), 4-morfolinilo, o -N(CH3)-(3- (1-metilpirrolidinilo)), m) CH2CORh (en la que Rh es -OCH3, -OCH2CH3, -NH2, - NHCH2CH(CH3)2, -NHCH2CF3, -NH-ciclopropilo, -NH-terc-butilo, -NHCH2CH2CH2OH, -N(CH3)2, -N(CH2CH3)2, -N(CH2CH2OH)2, -N(CH2CH2OCH3)2, -N(CH3)CH2CH2OH, -N(CH3)CH2CH2OCH3, - NHCH2CH2OCH3, 1-pirrolidinilo, 1-piperidinilo, 1-(piperidinil-4-metanol), 1-(piperidinil-3-carboxamida), 4-morfolinilo, 4-tiomorfolinilo, 4-tiomorfolinil-1,1-dioxido, 1-piperazinilo, 1-(4-acetilpiperazinilo), 1-(3-oxopiperazinilo), n) -SO2Ri (en la que Ri es -CH3, -CH2CH3, -CH(CH3)2, fenilo, 4-metilfenilo, 4-propilfenilo, -CF3, 2-tienilo, 3-tienilo, -NH2, -NHCH3, -N(CH3)2, -NHCH2CH2OCH3, -N(CH2CH2OCH3)2, 1-pirrolidinilo, 1-piperidinilo, 4-morfolinilo, 1-piperazil-4-etanol, 1-(4- acetilpiperazinilo), 1-(3-oxopiperazinilo)), o) -CORj (en la que Rj es -CH3, -CH2CH3, -CH(CH3)2, 2-tetrahidrofuranilo, 2-tienilo, 3-tienilo, -NH2, -NHCH3, -N(CH3)2, 1-pirrolidinilo, 1-piperidinilo, 4-morfolinilo, 1-piperazinil-4-etanol, 1-(4- acetilpiperazinilo), o 1-(3-oxopiperazinilo)), p) 4-tetrahidro-2H-tiopiranil-1,1-dioxido, q) 4-piperidinil-1-acetilo, r) 4-piperidinil-1-dimetilcarboxamida, y s) 3-tetrahidro-tiofenil-1,1-dioxido; v) una oxopiperazina sustituida de la formula (3), en la que R es -H, -CH3, -CH2CH3, -CH2CH2CH3, -CH2CH2OH o - CH2CH2OCH3; y vi) una piperidina sustituida de la formula (4), en la que R es -H, -COOCH3, -COOCH2CH3, -CONH2, -OH, -CH2OH, -CH2CH2OH, -CH2N(CH2CH3)2, -CH2-(1-piperazinilo), -CH2-(1-(3- oxopiperazinilo)),-NH2, -NHCOCH3, -NHCOCH2NH2, -NHCOCH2NHCH3, -NHCOCH2N(CH3)2, -NHCOCH2N(CH2CH2OH)2, -NHCOCH2N(CH2CH2OCH3)2, -NHCOCH2NHCH2CH2OH, -NHCOCH2-(1-(4-acetilpiperazinilo)), -NHCOCH2-(1-(3-oxopiperazinilo)), -NHCOCH2-(1- piperidinacarboxamida), -NHCOCH2-(N,N-dietil-1-piperidinilcarboxamida), -NHCOCH2-(1-(3-hidroxipiperidinilo)), -NHCOCH2-(1-(piperidinil-4-metanol)), -NHCON(CH3)2, -NHCSNHCH3, -NHCSNHPh, -NHCH2CONH2, 1 -pirrolidinilo, 1-piperidinilo, 1-(4- metilpiperazinilo), o 4-morfolinilo; y las sales y ésteres farmacéuticamente aceptables de los mismos.
ARP060105272A 2005-12-01 2006-11-29 Imidazolinas 4,4,5,5 tetrasustituidas y un proceso para su sintesis AR057990A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74122305P 2005-12-01 2005-12-01
US85274706P 2006-10-19 2006-10-19

Publications (1)

Publication Number Publication Date
AR057990A1 true AR057990A1 (es) 2008-01-09

Family

ID=37866229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105272A AR057990A1 (es) 2005-12-01 2006-11-29 Imidazolinas 4,4,5,5 tetrasustituidas y un proceso para su sintesis

Country Status (17)

Country Link
US (1) US7851626B2 (es)
EP (3) EP2130822A1 (es)
JP (1) JP4870778B2 (es)
KR (2) KR20100129331A (es)
CN (1) CN101316823B (es)
AR (1) AR057990A1 (es)
AU (1) AU2006319248B2 (es)
BR (1) BRPI0619236A2 (es)
CA (1) CA2630410C (es)
CR (1) CR9980A (es)
ES (1) ES2538714T3 (es)
MA (1) MA31550B1 (es)
NO (1) NO20082389L (es)
NZ (1) NZ568285A (es)
RU (1) RU2442779C2 (es)
TW (1) TWI326681B (es)
WO (1) WO2007063013A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666489C (en) * 2006-10-19 2012-10-02 F. Hoffmann-La Roche Ag Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
CA2666762C (en) * 2006-10-19 2014-12-30 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
KR20100042276A (ko) * 2007-07-06 2010-04-23 파라테크 파마슈티컬스, 인크. 치환 테트라사이클린 화합물의 합성방법
MX2010003868A (es) * 2007-10-09 2010-04-27 Hoffmann La Roche Cis-imidazolinas quirales.
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
MX2011007598A (es) 2009-01-16 2011-08-08 Daiichi Sankyo Co Ltd Derivados de imidazotiazol que tienen estructura de anillo de prolina.
KR20120050492A (ko) * 2009-08-26 2012-05-18 노파르티스 아게 테트라-치환된 헤테로아릴 화합물 및 ｍｄｍ2 및/또는 ｍｄｍ4 조절제로서의 그의 용도
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
CA2813256A1 (en) 2010-09-30 2012-04-05 St. Jude Children's Research Hospital Aryl-substituted imidazoles
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
CA2819436A1 (en) 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
EP2771008A4 (en) 2011-10-28 2015-04-08 Merck Sharp & Dohme MACROCYCLES FOR INCREASING P53 ACTIVITY AND USES THEREOF
US20140335074A1 (en) 2011-12-13 2014-11-13 Buck Institute For Research On Aging Methods for improving medical therapies
EP2793890B1 (en) 2011-12-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
TWI654180B (zh) 2012-06-29 2019-03-21 美商艾佛艾姆希公司 殺真菌之雜環羧醯胺
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
WO2014082889A1 (en) * 2012-11-28 2014-06-05 F. Hoffmann-La Roche Ag Novel imidazolines as dual inhibitors of mdm2 and mdmx
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
CN103012272B (zh) * 2012-12-21 2015-01-28 江苏国泰超威新材料有限公司 一种咪唑啉化合物的制备方法
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
EP2970237B1 (en) 2013-03-14 2017-09-27 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
AU2014286237B2 (en) 2013-07-03 2020-08-20 F. Hoffmann-La Roche Ag mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
CA2945527C (en) 2014-04-17 2022-05-17 The Regents Of The University Of Michigan Mdm2 inhibitors and therapeutic methods using the same
WO2016112251A1 (en) * 2015-01-09 2016-07-14 Genentech, Inc. 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
MX2018000360A (es) * 2015-07-10 2018-06-11 Arvinas Inc Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
MX2019015095A (es) 2017-06-16 2020-08-17 Unity Biotechnology Inc Metodo de sintesis para producir compuestos de cis-imidazolina enantiomericamente puros para uso farmaceutico.
AU2019247554A1 (en) 2018-04-06 2020-11-26 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
KR102039696B1 (ko) 2018-04-23 2019-11-04 충남대학교산학협력단 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법
CN114075121B (zh) * 2020-08-19 2025-08-29 中国科学院上海有机化学研究所 一类偶氮化合物的制备方法及其用途
KR102622992B1 (ko) 2021-03-29 2024-01-10 주식회사 퓨전바이오텍 이미다졸린 유도체 및 이의 중간체 제조방법
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
EP0786455B1 (en) * 1994-09-26 2003-12-03 Shionogi & Co., Ltd. Imidazole derivative
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
RU2305095C2 (ru) * 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
JP4361798B2 (ja) 2001-12-18 2009-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｍｄｍ２インヒビターとしてのシス−イミダゾリン
US6878735B2 (en) * 2002-05-31 2005-04-12 Board Of Trustees Of Michigan State University Multi-substituted imidazolines and method of use thereof
US7345078B2 (en) * 2002-05-31 2008-03-18 The Board Of Trustees Of Michigan State University NF-κB inhibitors and uses thereof
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
CN100562316C (zh) * 2003-06-17 2009-11-25 霍夫曼-拉罗奇有限公司 作为mdm2抑制剂的顺式咪唑啉
JP2006527712A (ja) * 2003-06-17 2006-12-07 エフ．ホフマン−ラ　ロシュ　アーゲー シス−２，４，５−トリアリール−イミダゾリン
CN1953965B (zh) * 2004-05-18 2012-07-04 霍夫曼-拉罗奇有限公司 新型顺式咪唑啉类化合物
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines

Also Published As

Publication number Publication date
RU2442779C2 (ru) 2012-02-20
CA2630410C (en) 2014-02-25
RU2008126383A (ru) 2010-01-10
JP2009517439A (ja) 2009-04-30
CA2630410A1 (en) 2007-06-07
HK1126216A1 (en) 2009-08-28
NO20082389L (no) 2008-08-18
EP2311814A1 (en) 2011-04-20
US7851626B2 (en) 2010-12-14
KR20100129331A (ko) 2010-12-08
MA31550B1 (fr) 2010-08-02
TW200804297A (en) 2008-01-16
EP1960368B1 (en) 2015-05-06
AU2006319248A1 (en) 2007-06-07
CN101316823A (zh) 2008-12-03
KR20080072894A (ko) 2008-08-07
US20070129416A1 (en) 2007-06-07
BRPI0619236A2 (pt) 2011-09-20
AU2006319248B2 (en) 2012-09-27
NZ568285A (en) 2011-08-26
CR9980A (es) 2008-06-18
CN101316823B (zh) 2013-05-22
JP4870778B2 (ja) 2012-02-08
EP1960368A1 (en) 2008-08-27
WO2007063013A1 (en) 2007-06-07
ES2538714T3 (es) 2015-06-23
EP2130822A1 (en) 2009-12-09
KR101109437B1 (ko) 2012-01-31
TWI326681B (en) 2010-07-01

Similar Documents

Publication Publication Date Title
AR057990A1 (es) Imidazolinas 4,4,5,5 tetrasustituidas y un proceso para su sintesis
AR068742A1 (es) Cis-imidazolinas quirales, composicion farmaceutica, proceso y uso para cancer
CU20220064A7 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CA2971110C (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
AR033295A1 (es) Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica
CU20220065A7 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
HRP20230090T1 (hr) Heterociklički spojevi kao imunomodulatori
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
JP2015509975A5 (es)
ES2601007T3 (es) Compuesto de piperazina que presenta un efecto inhibidor de PGDS
CO6241112A2 (es) Sales novedosas de piperazina como antagonistas d3/d2
Ishizumi et al. Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*, 2S*, 3R*, 4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl] butyl]-2, 3-bicyclo [2.2. 1] heptanedicarboximide (tandospirone) and related compounds
RU2012120307A (ru) Позитивные аллостерические модуляторы (рам)
PE20191787A1 (es) Derivados de indol n-sustituidos
AR079260A1 (es) Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos
ES2531410T3 (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintasa quinasa 3
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
AR115965A1 (es) Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática
MX2024003728A (es) Derivados de morfolinas sustituidas y usos de estos.
MX2024001829A (es) Derivado de triazol sustituido, metodo de preparacion del mismo, composicion farmaceutica del mismo y uso del mismo.
RU2011142151A (ru) Производные индазола-ингибиторы hsp90, содержащие их композиции и применение
Varlamov et al. The interaction of 4-hydroxymethyl isoindolines with dehydrobenzene. Synthesis of 3-phenylaminomethyldihydrobenzo [c] furanes
GB1031916A (en) Sulphonamides
AR119341A1 (es) Profármacos de moduladores del receptor de nmda

Legal Events

Date Code Title Description
FA Abandonment or withdrawal